Hammond Catherine, Kurten Megan, Kennedy Joshua L
Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, USA,
Curr Allergy Asthma Rep. 2015 Feb;15(2):502. doi: 10.1007/s11882-014-0502-0.
The human rhinovirus (HRV) is commonly associated with loss of asthma symptom control requiring escalation of care and emergency room visits in many patients. While the association is clear, the mechanisms behind HRV-induced asthma exacerbations remain uncertain. Immune dysregulation via aberrant immune responses, both deficient and exaggerated, have been proposed as mechanisms for HRV-induced exacerbations of asthma. Epithelium-derived innate immune cytokines that bias Th2 responses, including interleukin (IL)-25, IL-33, and thymic stromal lymphopoietin (TSLP), have also been implicated as a means to bridge allergic conditions with asthma exacerbations. In this review, we discuss the literature supporting these positions. We also discuss new and emerging biotherapeutics that may target virus-induced exacerbations of asthma.
人鼻病毒（HRV）通常与许多患者哮喘症状控制丧失相关，这需要加强护理并增加急诊就诊次数。虽然这种关联很明确，但HRV诱发哮喘加重背后的机制仍不确定。通过异常免疫反应导致的免疫失调，包括免疫缺陷和免疫亢进，已被提出作为HRV诱发哮喘加重的机制。上皮来源的固有免疫细胞因子可偏向Th2反应，包括白细胞介素（IL）-25、IL-33和胸腺基质淋巴细胞生成素（TSLP），也被认为是将过敏状态与哮喘加重联系起来的一种方式。在本综述中，我们讨论了支持这些观点的文献。我们还讨论了可能针对病毒诱发哮喘加重的新型生物疗法。
